DENTSPLY SIRONA (XRAY) Stock: Buy, Sell, or Hold?
XRAY - DENTSPLY SIRONA Inc.
$9.50
0.42 (4.63%)
â˛
5d:
+7.59%
30d:
-2.86%
90d:
-26.53%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 05, 2026
13d
Get Alerted When XRAY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: XRAY is fairly priced but lacks strong directional signals. At -5.0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: XRAY is fairly priced but lacks strong directional signals. At -5.0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$15.04
Based on 6.4% avg growth
INTRINSIC VALUE TODAY
$9.34
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: XRAY is currently trading at $9.50, which is considered slightly high relative to its 30-day fair value range of $8.54 to $9.65. From a valuation perspective, the stock is trading at a discount (Forward PE: 6.3) compared to its historical average (7.4). Remarkably, the market is currently pricing in an annual earnings decline of 5.0% over the next few years. This pessimistic expectation contrasts with the company's recent 15.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, XRAY is in a downtrend. The price is approaching resistance at $9.55. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.6% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $12.67 (+33.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, XRAY is in a downtrend. The price is approaching resistance at $9.55. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.6% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $12.67 (+33.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$8.54 -
$9.65
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
70.0%
Protect Your Profits
Holding XRAY? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.6%)
- BULLISH: Trading 33.3% below Wall St target ($12.67)
- WARNING: Composite score 50/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$8.54 -
$9.65
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$8.32
Resistance Level
$9.55
Current Trend
Downtrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
6.35
Wall Street Target
$12.67
(+33.3%)
Revenue Growth (YoY)
-4.1%
Earnings Growth (YoY)
15.2%
Profit Margin
-15.0%
Valuation Discount vs History
-5.0% cheaper
PE vs Historical
6.4 vs 7.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.0%
(market-implied from PE analysis)
1-Year Target
$9.02
(-5%)
2-Year Target
$8.57
(-10%)
3-Year Target
$8.15
(-14%)
3-Yr Target (if PE normalizes)
(PE: 6â7)
$9.49
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 8.7%)
$29.77
(+213%)
Base:
(SPY PE: 6.4, Growth: 8.7%)
$9.52
(+0%)
Bear:
(PE: 5.4, Growth: 8.7%)
$8.10
(-15%)
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 6.4 to 7.4
Stabilization Target:
$11.06
(+16.5%)
PE Expansion Potential:
+16.5%
Share & Embed Analysis
Last updated: October 22, 2026 6:47 PM ET
Data refreshes hourly during market hours. Next update: 7:47 PM
Data refreshes hourly during market hours. Next update: 7:47 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XRAY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Instruments & Supplies Stocks
Top-rated stocks in Medical Instruments & Supplies by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ISRG
Intuitive Surgical Inc |
STRONG BUY
34 analysts |
$479 | 32 SELL |
|
ALC
Alcon AG |
STRONG BUY
27 analysts |
$83 | 37 SELL |
|
RGEN
Repligen Corporation |
STRONG BUY
22 analysts |
$198 | 49 HOLD |
|
WST
West Pharmaceutical ServâĻ |
STRONG BUY
17 analysts |
$413 | 41 HOLD |
|
STVN
Stevanato Group SpA |
BUY
14 analysts |
$24 | 63 BUY |
Advanced XRAY Option Strategies
Professional options setups generated by AI based on today's XRAY price and gamma walls.
